Home Major Milestone: Tianwu Tech Secures First Overseas Partnership for Biologics Pipeline

Major Milestone: Tianwu Tech Secures First Overseas Partnership for Biologics Pipeline

Dec 02, 2025 15:03 CST Updated 15:03
Matwings Technology

AI Protein Design Service Provider

Image
Click the blue words above to follow us
Image
Image
Abstract

Image

Recently, Matwings Technology, a portfolio company of Bencao, has partnered with a globally leading U.S. biotechnology company founded by top entrepreneurs in the life sciences field.Reach an Innovative Biopharmaceutical Pipeline Cooperation Agreement

According to the agreement, Matwings Technology will be entitled to receive commercial returns including development upfront payments, development milestones, and product commercialization revenues, as well as additional potential licensing revenues. This collaboration not onlyMarks Matwings Technology's official entry into the global strategic market, and also indicates that AI technology is comprehensively driving biopharmaceutical R&D into a new stage.

图片

The core technology driving force of Matwings Technology stems from itsLeading AI Protein Design Platform AIACCLBIO®This platform is pre-trained on VenusPod, the world's largest protein sequence dataset, and integrates core capabilities such as AI-directed evolution, enzyme mining, and de novo design. It has already accumulated a wealth of successful cases in enhancing protein performance—particularly in extreme tolerance aspects like high-temperature resistance, strong acid and alkali resistance, and more. These capabilities demonstrate the platform's broad application potential in fields such as biomedicine, industrial enzyme design, environmental catalysis, and biosynthesis.This collaboration is a strong recognition of its outstanding ability to achieve efficient design in complex biopharmaceutical scenarios.


CTO of Matwings Technology, Liu HaoSaid: "This cooperation with international partners goes beyond simple technical recognition; it symbolizes even more.Both parties to'AI-Driven Biomedical Innovation'ThisShared recognition of future vision.This not onlyDemonstrates the capability of the AIACCLBIO® platform to solve real-world drug discovery challenges.More importantly,It established Matwings Technology as its innovation engine.Jointly advance a highly challenging R&D pipeline

Image

Previous Recommendations



Congratulations | Matwings Technology Wins Grand Prize at "Haiju Yingcai" Global Finals
Matwings Technology Partners with Bayer: AI-Powered Protein Design Drives Innovation in Health Consumer Products
Matwings Technology Completes Over 100 Million Yuan in Series A Financing, "Beyond Structure, Predicting Function" | Betelnut Invested Company
Image
Materia MedicaResourcesThisFocus on investing in hard-core technological innovations in the globally leading life sciences sector. We allocate approximately half of our investments to Biotech, namely innovative pharmaceuticals, including novel drug modalities and drug discovery platforms; the other half is allocated to TechBio, which refers to disruptive innovations arising from cross-disciplinary technology integration, including but not limited to IT technologies, sensors, data science, artificial intelligence, and their integration with biology to create next-generation devices, diagnostic tools, and life science research instruments. Based in China and targeting the global market, Matwings Technology aims to advance cutting-edge technological progress in the life sciences field and make a positive contribution to human health and well-being.

Follow 「Herbal Capital" WeChat Official Account and set it as 'Star ⭐' to get the latest updates第一时间收获最新推送."